Analytical Data
-
Gene name
HLA-A*02:01&B2M&P53 WT(HMTEVVRRC) Monomer
- Application
-
Alternative Names
MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&HMTEVVRRC
-
Molecular Weight
52-62 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/P53 WT (HMTEVVRRC) monomeric recombinant protein is situated at the intersection of immunology and cancer research. HLA-A*02:01 is one of the most prevalent human leukocyte antigen (HLA) class I molecules, playing a crucial role in presenting peptides derived from intracellular proteins to CD8+ T cells, thus modulating adaptive immune responses. Mutations in the tumor suppressor gene TP53 are common across various cancers, leading to altered peptide presentation and immune evasion. The peptide HMTEVVRRC, derived from the wild-type p53 protein, is of particular interest due to its potential as a neoantigen that can stimulate an immune response. By creating a recombinant monomeric form of this complex, researchers aim to investigate its structural properties and binding affinities, facilitating the understanding of how the immune system recognizes and responds to p53-derived peptides in the context of cancer. Understanding this interaction could pave the way for novel immunotherapies targeting tumors harboring p53 mutations, enhancing the specificity and efficacy of cancer treatments by harnessing the patient’s own immune response. Such investigations hold promise for advancing personalized medicine approaches in oncology.
